Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer

Pooja Advani, Lauren Cornell, Saranya Chumsri, Alvaro Moreno Aspitia

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase transmembrane receptor that is overexpressed on the surface of 15%–20% of breast tumors and has been associated with poor prognosis. Consistently improved pathologic response and survival rates have been demonstrated with use of trastuzumab in combination with standard chemotherapy in both early and advanced breast cancer. However, resistance to trastuzumab may pose a major problem in the effective treatment of HER2-positive breast cancer. Dual HER2 blockade, using agents that work in a complimentary fashion to trastuzumab, has more recently been explored to evade resistance in both the preoperative (neoadjuvant) and adjuvant settings. Increased effectiveness of dual anti-HER2 agents over single blockade has been recently reported in clinical studies. Pertuzumab in combination with trastuzumab and taxane is currently approved in the metastatic and neoadjuvant treatment of HER2-positive breast cancer. Various biomarkers have also been investigated to identify subsets of patients with HER2-positive tumors who would likely respond best to these targeted therapy combinations. In this article, available trial data regarding efficacy and toxicity of treatment with combination HER2 agents in the neoadjuvant and adjuvant setting have been reviewed, and relevant correlative biomarker data from these trials have been discussed.

Original languageEnglish (US)
Pages (from-to)321-335
Number of pages15
JournalBreast Cancer: Targets and Therapy
Volume7
DOIs
StatePublished - Sep 22 2015

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Biomarkers
Receptor Protein-Tyrosine Kinases
human ERBB2 protein
Survival Rate
Drug Therapy
Trastuzumab
Therapeutics

Keywords

  • Adjuvant
  • Breast cancer
  • Dual blockade
  • HER2
  • Neoadjuvant
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology

Cite this

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. / Advani, Pooja; Cornell, Lauren; Chumsri, Saranya; Moreno Aspitia, Alvaro.

In: Breast Cancer: Targets and Therapy, Vol. 7, 22.09.2015, p. 321-335.

Research output: Contribution to journalArticle

@article{968ffd2eb59b41fca466a6663a5d5ee1,
title = "Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer",
abstract = "Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase transmembrane receptor that is overexpressed on the surface of 15{\%}–20{\%} of breast tumors and has been associated with poor prognosis. Consistently improved pathologic response and survival rates have been demonstrated with use of trastuzumab in combination with standard chemotherapy in both early and advanced breast cancer. However, resistance to trastuzumab may pose a major problem in the effective treatment of HER2-positive breast cancer. Dual HER2 blockade, using agents that work in a complimentary fashion to trastuzumab, has more recently been explored to evade resistance in both the preoperative (neoadjuvant) and adjuvant settings. Increased effectiveness of dual anti-HER2 agents over single blockade has been recently reported in clinical studies. Pertuzumab in combination with trastuzumab and taxane is currently approved in the metastatic and neoadjuvant treatment of HER2-positive breast cancer. Various biomarkers have also been investigated to identify subsets of patients with HER2-positive tumors who would likely respond best to these targeted therapy combinations. In this article, available trial data regarding efficacy and toxicity of treatment with combination HER2 agents in the neoadjuvant and adjuvant setting have been reviewed, and relevant correlative biomarker data from these trials have been discussed.",
keywords = "Adjuvant, Breast cancer, Dual blockade, HER2, Neoadjuvant, Trastuzumab",
author = "Pooja Advani and Lauren Cornell and Saranya Chumsri and {Moreno Aspitia}, Alvaro",
year = "2015",
month = "9",
day = "22",
doi = "10.2147/BCTT.S90627",
language = "English (US)",
volume = "7",
pages = "321--335",
journal = "Breast Cancer: Targets and Therapy",
issn = "1179-1314",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer

AU - Advani, Pooja

AU - Cornell, Lauren

AU - Chumsri, Saranya

AU - Moreno Aspitia, Alvaro

PY - 2015/9/22

Y1 - 2015/9/22

N2 - Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase transmembrane receptor that is overexpressed on the surface of 15%–20% of breast tumors and has been associated with poor prognosis. Consistently improved pathologic response and survival rates have been demonstrated with use of trastuzumab in combination with standard chemotherapy in both early and advanced breast cancer. However, resistance to trastuzumab may pose a major problem in the effective treatment of HER2-positive breast cancer. Dual HER2 blockade, using agents that work in a complimentary fashion to trastuzumab, has more recently been explored to evade resistance in both the preoperative (neoadjuvant) and adjuvant settings. Increased effectiveness of dual anti-HER2 agents over single blockade has been recently reported in clinical studies. Pertuzumab in combination with trastuzumab and taxane is currently approved in the metastatic and neoadjuvant treatment of HER2-positive breast cancer. Various biomarkers have also been investigated to identify subsets of patients with HER2-positive tumors who would likely respond best to these targeted therapy combinations. In this article, available trial data regarding efficacy and toxicity of treatment with combination HER2 agents in the neoadjuvant and adjuvant setting have been reviewed, and relevant correlative biomarker data from these trials have been discussed.

AB - Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase transmembrane receptor that is overexpressed on the surface of 15%–20% of breast tumors and has been associated with poor prognosis. Consistently improved pathologic response and survival rates have been demonstrated with use of trastuzumab in combination with standard chemotherapy in both early and advanced breast cancer. However, resistance to trastuzumab may pose a major problem in the effective treatment of HER2-positive breast cancer. Dual HER2 blockade, using agents that work in a complimentary fashion to trastuzumab, has more recently been explored to evade resistance in both the preoperative (neoadjuvant) and adjuvant settings. Increased effectiveness of dual anti-HER2 agents over single blockade has been recently reported in clinical studies. Pertuzumab in combination with trastuzumab and taxane is currently approved in the metastatic and neoadjuvant treatment of HER2-positive breast cancer. Various biomarkers have also been investigated to identify subsets of patients with HER2-positive tumors who would likely respond best to these targeted therapy combinations. In this article, available trial data regarding efficacy and toxicity of treatment with combination HER2 agents in the neoadjuvant and adjuvant setting have been reviewed, and relevant correlative biomarker data from these trials have been discussed.

KW - Adjuvant

KW - Breast cancer

KW - Dual blockade

KW - HER2

KW - Neoadjuvant

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84942416058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942416058&partnerID=8YFLogxK

U2 - 10.2147/BCTT.S90627

DO - 10.2147/BCTT.S90627

M3 - Article

AN - SCOPUS:84942416058

VL - 7

SP - 321

EP - 335

JO - Breast Cancer: Targets and Therapy

JF - Breast Cancer: Targets and Therapy

SN - 1179-1314

ER -